Search results
Some Breather For Novavax's COVID-19 Vaccine, Inks Multibillion-Dollar Deal With Sanofi And...
Benzinga via Yahoo Finance· 5 days agoThe terms of the agreement include: A co-exclusive license to co-commercialize Novavax’s current...
1 Wall Street Analyst Thinks Novavax Stock Is Going to $10. Is It a Sell? | The Motley Fool
The Motley Fool· 7 hours agoNovavax (NVAX -4.30%) took a turn in the investor spotlight in early May, when the vaccine...
Does Soaring Novavax Stock Have Enough Fuel to Climb Higher? | The Motley Fool
The Motley Fool· 2 days agoThe market was responding to terrific news from Sanofi (NASDAQ: SNY), a global pharmaceutical giant...
Novavax Soars on Sanofi Deal: A Smart Buy or Post-Hype Correction?
FX Empire via Yahoo Finance· 15 hours agoThe past five days have been a rollercoaster for Novavax investors, as the share price of the...
Novavax Sheds Going Concern Warning as NVAX Stock Pops on Sanofi Licensing Deal
InvestorPlace· 5 days agoCovid-19 vaccine. The agreement will also provide Sanofi with a sole license to the vaccine for use...
Novavax Stock Just Tripled. Is It Too Late to Buy?
The Motley Fool via AOL· 16 hours agoSo, it's no surprise that such news prompted some investors to pile into the stock. But does this rapid gain mean it's too late to buy Novavax shares now...
French, US drug firms team up for Covid-flu shot
Medical Xpress· 6 days agoUnder a licensing deal worth up to $1.2 billion, the companies will co-commercialize Novavax's COVID-19 vaccine worldwide ...
Novavax strikes $1.2 billion deal with Sanofi in major turnaround
Axios· 5 days agoDriving the news: Novavax will receive an upfront payment of $500 million and up to $700 million in...
Novavax Stock More Than Doubles On Deal With Sanofi To Co-commercialize Covid-19 Vaccine
RTT News· 6 days agoNovavax also announced a co-exclusive licensing agreement with Sanofi to co-commercialize Covid-19 vaccine and develop ...
Novavax gets a lifeline with Sanofi vaccine pact
BioPharma Dive via Yahoo Finance· 6 days agoSanofi will ally with the under-pressure biotech, paying $500 million upfront for rights to co-commercialize Novavax’s COVID shot and develop combination...